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Abstract 
Purpose of review  
Chronic obstructive pulmonary disease (COPD) is the fifth cause of mortality in the world. This article 
reviews diet as a risk or protective factor for COPD, mechanisms of malnutrition, undernutrition 
consequences on body functioning and how to modulate nutritional status of COPD patients. 
Recent findings 
Different dietary factors (dietary pattern, foods, nutrients) have been associated with COPD and the 
course of the disease. Mechanical disadvantage, energy imbalance, disuse muscle atrophy, hypoxemia, 
systemic inflammation and oxidative stress have been reported to cause systemic consequences such as 
cachexia and compromise whole body functioning. Nutritional intervention makes it possible to modify 
the natural course of the disease provide that it is included in respiratory rehabilitation combining 
bronchodilators optimization, infection control, exercise and in some patients correction of 
hypogonadism.  
Summary 
Diet, as a modifiable risk factor, appears more as an option to prevent and modify the course of COPD. 
Reduction of mechanical disadvantage, physical training and anabolic agents should be used conjointly 
with oral nutrition supplements to overcome undernutrition and might change the prognosis of the 
disease in some cases. Major research challenges address the role of systemic inflammation and the 
best interventions for control it besides smoking cessation. 
 
Keywords: Nutrition disorders, COPD, inflammation, pulmonary rehabilitation, enteral feeding, oral 
nutrition supplement, anabolic agents, diet 
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1. Introduction 
Nutritional status has been associated with respiratory function in COPD with complex 
interplays between environmental and genetic factors (Fig. 1) [1•]. Studies have shown that 
malnutrition served as negative prognostic factor in COPD. Conversely, diet could be a protective or a 
harmful factor regarding the risk of incident COPD and modifying factor in established disease [2-4]. 
The question is how we could intervene with nutritional factors to improve prognosis. This review will 
discuss diet as a risk factor in COPD, mechanisms of malnutrition, consequences of undernutrition on 
body functioning and how to modulate nutritional status of these patients. 
  
2. Diet as a risk factor for COPD 
Cigarette smoking is the most important risk factor for COPD, but up to one third of patients 
with COPD have never smoked [5]. These suggest that other factors, such as diet, also are involved. In 
the last decade, there has been a growing interest in identifying foods related to lung function or COPD 
symptoms [5,6,7••].  Nutritional epidemiologists propose to assess overall diet instead of the individual 
foods or nutrients due to interaction between nutrients [8]. This approach has been used in three recent 
studies which has used dietary patterns to assess diet in relation with respiratory phenotypes [6,7••,9].  
Among the Chinese Singaporeans, a ‘meat-dim sum’ pattern (meat, dim sum foods, and noodle 
dish) was associated with an increased risk of incident cough with phlegm [9]. In both a large cohort of 
US men and US women, a "prudent" pattern (high intake of fruits, vegetables, fish and whole grain 
products) was associated with a decrease risk of newly diagnosed COPD whereas a Western pattern 
(high intake of refined grains, cured and red meats, desserts and French fries) was associated with an 
increase of COPD [6,7••].  
Most investigations have focused on the possibility that fruits and vegetables exert beneficial 
effects on lung health and a very little attention has been paid to other foods or nutrients. Recently, it 
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has been suggested that dietary fibre was independently associated with better lung function and 
reduced prevalence COPD [10,11]. Previous studies have mostly focused on the potentially protective 
effects of foods rich in antioxidants, and not on foods with a potential deleterious effect. However, it 
was recently reported both in three longitudinal surveys [7••,12,13] and in a cross-sectional survey[14] 
that frequent consumption of cured meats was associated with higher prevalence and incidence of 
COPD. All these studies provide additional support to the hypothesis that diet, a modifiable risk factor, 
is associated with respiratory diseases. Nutritional epidemiology may play an important role in 
advancing our understanding of the relevant pathophysiological mechanisms involved in the 
development and progression of respiratory diseases.  
 
3. Epidemiology and mechanisms of nutritional depletion in COPD 
Malnutrition in COPD is one of negative predictive factors and mechanisms of nutritional depletion are 
multifactorial processes that will be described in the next following paragraphs.  
3.1. Epidemiology  
Weight loss in COPD was already recognized as a clinical finding and it is more frequent in 
emphysematous patients as contrary to the blue bloaters [15]. The prevalence of nutritional depletion 
was about 20-35% in outpatients COPD and up to 70% in patients with acute respiratory failure or in 
patients awaiting a lung transplantation [4,16-18]. 
3.2. Mechanisms of nutrition depletion  
Nutrition depletion occurs by including several factors such as energy imbalance, disuse atrophy of the 
muscles, hypoxemia, systemic inflammation, oxidative stress and hypogonadism in some patients. 
3.2.1. Energy imbalance and metabolism changes 
The largest component of energy expenditure (EE) is the basal metabolic rate (BMR), which is 
the energy needed for basic processes of life and it accounts for 60-70% of total daily EE [19]. 
Increased energy expenditure due to mechanic disadvantage, metabolic inefficiency with some fibre-
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type shift in skeletal muscle from type I to type II, together with systemic inflammation may be 
determinants of an hypermetabolic state that may not be balanced by dietary intake [20••]. In COPD 
patients, resting energy expenditure (REE) has been reported to be 15–20% above predicted values due 
to the increased energy required for breathing [21,22]. Total daily expenditure was also higher in 
COPD patients compared to healthy subjects and it may be caused by increased level of non-resting 
daily expenditure [23]. Energy expenditure changes due to impaired mechanical efficiency may be 
partially reversed by reducing hyperinflation with medication, breathing techniques or lung volume 
reduction. This could reduced oxygen cost for breathing and increased oxygen availability which 
favours carbohydrate metabolism and recovery in body composition with lower fat and and higher fat-
free masses [24-26].  
Chronic obstructive lung disease may induce insulin resistance and changes glucose metabolism 
[27]. Data from the Third National Health and Nutrition Examination Survey showed that impaired 
glucose regulation was associated with impaired lung function [28]. Glucose plasma concentrations 
were similar in non-hypoxemic COPD patients and healthy subjects. Abnormal glucose metabolism 
may be a risk factor for cardiovascular disease and type II diabetes in COPD [29].  
Some data showed that increased proteolysis in cystic fibrosis (CF) patients was related to 
impaired glucose tolerance due to resistance to the anabolic effects of insulin on proteolysis [30]. High 
catecholamine level in COPD may induce hypermetabolic response which causes increased EE and 
muscle-protein catabolism [31,32]. These findings suggested some role of insulin resistance in FFM 
(fat free mass) depletion.  
COPD patients often have dyslipidemia related to metabolic syndrome (abdominal obesity, 
increased triglycerides, dyslipidemia) and it is due to some changes in lipid metabolism. [33]. 
Jackobsson et al found a decrease in lipolysis and increased glucose levels in patients with advanced 
COPD with chronic respiratory failure, signaling a role of insulin resistance in the reduction of lipolysis 
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[34]. These findings suggested that FM (fat mass) relatively preserved or increased due to decrease 
lipolysis. 
3.2.2. Disuse atrophy of muscles 
 Patients with very severe COPD are very inactive as compare to healthy people of the same 
advanced age [35]. Several studies have shown that these patients have an increased protein breakdown 
pathways, in particular the NF-kB-activated ubiquitin/proteasomal pathway and apoptosis [36].  
3.2.3. Hypoxemia  
 It has been suggested that the hypoxemia of COPD is one causative factor for cachexia. 
Hypoxemia may increase the generation of ROS and TNF-α which in turn may give rise to 
inflammatory changes leading to cachexia [37]. It may stimulate the sympathetic nervous system and 
this has been shown to produce systemic inflammation [38]. 
3.2.4. Systemic inflammation and oxidant stress  
 Systemic inflammation has important metabolic consequences and become the primary focus of 
research into the genesis of cachexia in COPD. The molecules receiving the greatest amount of 
attention are TNF-α, IL-1β, IL-6, CRP, and ROS and reactive nitrogen species (see ref.20 for review) 
and may play a role in cachexia. COPD has been proposed in this context a new syndrome called 
“chronic systemic inflammatory syndrome” including at least 3 out 6 following factors: age older than 
40, more than 10 year-smoking history, symptoms and pulmonary functions compatible with COPD, 
chronic heart failure, insulin resistance, and increased plasma CRP [39••,40]. There may be also a link 
between inflammation and leptin levels. Nevertheless, major gaps persist related to environmental and 
genetic factors underlying cachexia susceptibility, to sequential molecular steps [20••]. 
3.2.4. Hypogonadism  
 There is evidence that insufficiency of one or more of three hormones may contribute to 
cachexia. Creutzberg et al have provided an overview of endocrine factors in COPD [41]. Low levels 
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of circulating hormones do not prove cause and effect in cachexia in COPD. Inversely, anabolic 
hormones replacement may have a role in selected patients as reported in various publications. 
 
4. Impacts of malnutrition in COPD  
Impact of malnutrition in COPD on body functioning will be emphasized on body composition, on 
lung parenchyma, respiratory function, respiratory mechanics, physical capacity, and also morbidity 
and mortality. 
4.1. Body composition 
Patients with COPD are known to be generally underweight and have reduced FFM as showed 
by several studies [42,43]. Study by Sergi et al showed that COPD patients had a lower FFM as 
compared to healthy subjects (38% versus 31%) [42]. In a large out-patient population of patients with 
COPD in Netherlands, they found prevalence of normal BMI and low FFMI was 15%, and of low BMI 
and low FFMI 11% [17]. 
4.2. Lung parenchyma, respiratory function and respiratory mechanics 
Massaro et al described loss of pulmonary alveoli in calorie restriction and regenerated after ad 
libitum refeeding [44]. Undernutrition led to lung and chest wall mechanical changes, such as distorted 
structure of diaphragm and intercostals, reduction of surfactant and decrease in elastic fibre content of 
pulmonary parenchyma [45]. Inspiratory muscle weakness and maximum inspiratory pressure 
generation was an independent determinant of survival in severe COPD [46]. The diaphragm as a main 
inspiratory muscle is suffered from muscle protein degradation and loss of contractile protein [47]. In 
study by Cano et al the degree of respiratory impairment (FEV1, FVC and 6-min walking test) was 
correlated with nutritional status especially FFM [48].  
4.3. Physical capacity 
Daily physical activity can be considered as ‘‘the totality of voluntary movement produced by 
skeletal muscles during everyday functioning’’ [49]. It is widely known that in patients with COPD, 
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lower levels of physical activity in daily life are related to higher risk of hospital readmission and 
shorter survival. The effect of skeletal muscle dysfunction contributes to declining body functioning as 
we defined as physical activity. Physical activity greatly influences patient outcomes because level of 
physical activities was shown to predict the risk for hospitalization [50,51]. Overall impairment of body 
functioning can be described in Figure 2 as adapted from  International Classification of Functioning 
(ICF) [52]. 
4.4. Morbidity and mortality 
Mortality of COPD patients and occurrence of acute exacerbation requiring hospitalization are 
higher in underweight patients. During hospitalization, COPD patients are most likely to loose weight 
because of the higher metabolic demand due to increased ventilatory disadvantage or infection and 
underweight patients also had a higher risk of new exacerbation [53]. Landbo et al described that in 
mild to moderate COPD the best prognosis was found in normal weight or overweight subjects, 
whereas in severe COPD, overweight or obese patients were associated with a better survival. These 
patients may be somehow protected from weight loss because of higher energy reserves [54].  
 
5. How to intervene 
The questions on how to intervene in these patients exist and we will discuss how and possible methods 
to modify disease progression or prognosis. 
5.1. Nutrition requirements 
The question on how much we should give nutritional repletion still remains. In the study by 
Planas et al, it was described that total daily energy intake of REE x 1.3 was preferable than REE x 1.7 
in mild stable COPD patients. They found that administration of nutritional supplements, high in 
proteins, with predominance of carbohydrates over fat, and enriched in antioxidants to achieve total 
daily defined energy intake in patients in group REE x 1.3 was followed by a significant improvement 
of body weight, handgrip strength, decrease airflow limitation and increase quality of life [55]. Total 
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calories being administered as 20% proteins seemed to be the optimal in nutritional supplements for 
stable malnourished COPD patients. Small portion of carbohydrate and protein-rich supplementation 
seemed to have an impact on weight gain after 8 weeks when compared to normal size supplements of 
similar macronutrient composition, probably because many patients still usually took ordinary meals 
outside the supplementation [56]. High load of portion will compromise diaphragm movement and 
caused postprandial dyspnea because it will prevent the diaphragm to move easily due to gastric filling 
pressure [57]. 
5.2. Methods 
Metabolic syndrome carries a lot of consequences in managing nutrition in COPD patients because of 
glucose level, hypertension, atherogenic dyslipidemia or other co-morbidities such as congestive heart 
failure. Methods that are known for nutritional intervention in COPD patients varied between studies. 
5.2.1. Oral nutrition supplements 
Nutritional support includes food enrichments, oral nutritional supplements, tube feeding and 
parenteral nutrition.[58] There is limited evidence that wasting COPD patients will benefit only with 
enteral nutrition as showed by meta-analysis by Ferreira et al[59] and reported in ESPEN 
recommendations in 2006[57]. Table I described some nutritional supplementation studies in COPD 
patients which were integrated or non-integrated with pulmonary rehabilitation. Refeeding in 
malnourished COPD patients is not easy and difficult to maintain due to many factors. The 2005 
Cochrane Review on nutritional supplementation for stable COPD had some important limitations 
relative to the small numbers of patients included, 214 in supplement arm versus 205 in control group, 
the non-integration of nutritional intervention in a pulmonary rehabilitation process, the short duration 
of intervention between 2 weeks to 3 months, and the lack of relevant endpoints to measure the effects 
of nutrition supplementation as quality of life, body composition or exercise capacity [57,68]. These 
limitations should encourage larger studies with a multimodality approaches and clinically relevant 
end-points.  
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5.2.2. Exercise 
Physical training will also have positive effects as anabolic process as it can increase FFM and 
functional status although it did not directly correlated [69]. Some others studies showed that physical 
training only will cause negative energy balance because of increase total energy expenditure, but this 
effect can be overcome by giving supplementation rich in carbohydrate. Glycogen storage is low in 
muscle of COPD patients and therefore carbohydrate can serve as better energy source [70]. 
5.2.3. Anabolic agents 
Anorexia is one of many factors contributes to cachexia in COPD. The use of appetite 
stimulating therapy in cachexia COPD patients is now getting more attention [71]. Progestogens 
(megestrol acetate) can be used to treat anorexia-cachexia. This agent can stimulate appetite and has 
antagonist effects of pro-inflammatory cytokines [72]. Androgenic hormones has been reported with 
some successes when combined with exercise, but problems of extra physiologic doses remain [73]. 
(Table II) 
5.2.4. Multimodality approaches 
A holistic approaches such as the combination of adequate nutritional support with reduction of 
mechanical insufficiency (with drugs, lung volume reduction, breathing technique), physical activity, 
anabolic agents or appetite stimulants and non-invasive ventilation will give these patients potential 
improvements strategy [24,25,79]. 
5.2.5. New tools 
Studies also have shown encouraging effects of n-3 polyunsaturated fatty acids (PUFAs) on 
cytokine release, markers of immune function, on exercise capacity and FFM of COPD patients [80]. 
Therefore nutrition support with PUFA can be considered to give positive effect for these patients. 
Oxygen supplementation could reduce dynamic hyperinflation at rest and during or after exercise due 
to changes in ventilatory pattern [81]. A significant weight gain was observed in malnourished COPD 
patients after NPPV initiation due to reduce hyperinflation which can help diaphragm to work more 
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efficiently and avoid dyspnea when eating (gastric filling) [82]. A better knowledge of molecular steps 
and targets involved in systemic consequences of COPD is of paramount importance to have better 
treatments. As an example, it appeared that the peroxisome proliferator-activated receptors (PPARs) 
are involved in cachexia, decreased oxidative muscle metabolism, oxidative stress and systemic 
inflammation suggesting  role for PPARs agonists [83]. 
 
Conclusion and non-answered questions 
Nutritional depletion has been widely reported in COPD patients. Diet may also play a role both 
in the development and the progression of the disease. Holistic management for these patients should 
include nutritional modulation beside reduction of mechanical disadvantage with long-acting 
bronchodilators, lung volume reduction, physical activity, anabolic agents or appetite stimulants and 
non-invasive ventilation. Furthermore, metabolic syndrome must be considered in the management of 
COPD in order to avoid any co-morbidities complication.  
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Legends of figures  
 
Figure 1. Gene-environnement interactions on body composition and the risk of COPD 
 
Figure 2. COPD as systemic disease in the context of the International Classification of 
Functioning, ICF-2, WHO 2001[52,83] 
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Fig.2 
Abbreviations: BMI: body mass index, 6MWT : 6 minutes walking test,  FEV1%: 
percentage of predicted FEV1 
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Table I. Nutritional supplementation studies with more than 2 weeks supplementation in COPD patients, integrated (filled in grey) and non 
integrated with rehabilitation programme (includes only studies after year 1990)  
Author, year  Patient’s 
characteristics, 
settings 
Study design n, supplementation group/control, 
intervention 
Judgements criteria  
Results 
 
Faager et al, 
2006[58] 
COPD patients with 
FEV1 < 70% , 
outpatients 
Randomized, 
double-blind, 
placebo-controlled 
study 
23, 13/10, creatine supplementation & 
exercise training 
Physical performance, lung function test 
No significant improvement 
Fuld et al, 
2005[59] 
Moderate to severe 
COPD, outpatients 
Randomized 
double-blind, 
placebo-controlled 
study 
38, 20/18, creatine nutritional 
supplementation, pulmonary 
rehabilitation 
Fat-free  mass, peripheral muscle strength and endurance, health 
status 
Significant improvement in all parameters, except exercise 
capacity 
Matsuyama et 
al, 2005[60] 
COPD patients 
FEV1 < 60% 
Randomized, 
double-blind 
controlled study 
64, 32/32, nutritional support with 
omega-3 PUFA-rich diets 
Leukotriene B4 levels, tumor necrosis factor-alpha  and 
interleukin-8 levels 
Decreased  significantly in the n-3 group 
Pison, 2004[61] Chronic respiratory 3-month 122, 60/62, health education + 6MWD, quality of life, body composition, exercise capacity, 
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failure at home, on 
NIV and/or LTOT 
randomized, 
controlled study, at 
home 
pulmonary rehabilitation + androgens + 
oral nutritional supplements, 560 
kcal/day versus health education alone 
exacerbation rate, survival 
Inclusions completed, results pending 
Vermeeren et 
al, 2004[62] 
Nutritionally 
depleted COPD 
patients, hopitalized 
patients 
Randomized 
double-blind, 
placebo-controlled 
study 
57, Energy and protein-rich nutritional 
supplements during hospitalization for 
an acute exacerbation  
Body composition, respiratory and skeletal muscle strength, lung 
function and symptoms 
No significant improvements in lung function or muscle strength  
Steiner, 
2003[63] 
Nutritionally 
depleted COPD 
patients, oupatients 
Prospective, 
controlled study   
85, 42 / 43, oral supplementation, 570 
kcal / j, pulmonary rehabilitation 
Body weight, body composition, quality of life (CRQ), 
quadriceps muscle forces, hand grip, shuttle test  
Improvement of shuttle test and quality of life  
Creutzberg, 
2003[64] 
Nutritionally 
depleted COPD 
patients, oupatients 
Prospective, 
controlled study 
69 / 28, oral supplementation 570 
kcal/day, pulmonary rehabilitation  
Body weight, body composition, lung function, hand grip, 
respiratory muscle forces, maximal exercice test, quality of life  
Improvements of body weight, fat free mass, hand grip, 
respiratory muscle forces 
Rogers, 
1992[65] 
Malnourished 
COPD patients, 
hospitalized then 
Prospective, 
controlled study 
Oral supplementation, no pulmonary 
rehabilitation 
Body weight,  respiratory muscle forces, hand grip, lung function, 
6MWT 
Improvement of body weight, hand grip, respiratory muscle 
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outpatients forces, 6MWT 
Fuenzalida, 
1990[66] 
Nutritionally 
depleted, 
hospitalized then 
outpatients 
Prospective, 
controlled study 
9, 5/4, oral supplementation, 1080 
kcal/day, no pulmonary rehabilitation 
Body weight, anthropometry, immune response 
Improvement of imuunity status  
Whittaker, 
1990[67]  
 
Nutritionally 
depleted, 
hospitalized  
Prospective, 
controlled study  
10,  6 / 4, nasogastric tube 
supplementation + 1000 kcal versus + 
100 kcal, 16 days, no rehabilitation 
Body weight,  respiratory muscle forces, hand grip, lung function  
Improvement of body weight and respiratory muscle forces  
Abbreviations: PImax: maximal inspiratory mouth pressure; PEmax: maximal expiratory mouth pressure; MVV : Maximal Voluntary Ventilation ; 
6MWT : 6 minutes walking test ; REE : Resting Energy Expenditure      
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Table II. Effects of anabolic agents in COPD patients integrated (filled in grey) and non-integrated with rehabilitation programme  
Author, year  Patient’s characteristics, settings Study design n, supplementation 
group/control, intervention 
Judgements criteria  
Results 
Casaburi, 
2004[74] 
 
FEV1 of 60% predicted or less, FEV1 
to vital capacity ratio of 60% or less, 
outpatients 
Prospective, randomized, 
controlled, double-blind 
study, rehabilitation in 2 out 
4 groups 
 
47, 100 mg/week testosterone 
enanthate in sesame oil  
Body weight, body composition, 
respiratory muscle function 
Significant increased lean body mass 
Creutzberg, 
2003[75] 
FEV1 < 70% predicted, FEV1increase 
≤ 10% after inhalation ß2-agonist, 
outpatient 
 
 
Prospective, randomized, 
controlled, double-blind 
study 
Pulmonary rehabilitation 
63, 33/30, 50 mg of nandrolone 
decanoate IM 
Body composition, muscle function, 
exercise capacity, health status, 
erythropoietic parameters, laboratory 
parameters 
Improvements in muscle function and 
exercise capacity 
Yeh, 2002[76] 
 
FEV1 < 50% predicted, FEV1/FVC 
ratio < 70%, weight 90% ideal body 
weight, outpatient 
Prospective, open-label, 4-
month clinical trial 
128, oxandrolone, 10 mg bid Body weight, body composition, 
spirometry, 6MWT 
Significant weight gain 
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Ferreira, 
1998[77] 
BMI below 20 kg/m2, the maximal 
inspiratory pressure (PImax) was 
below 60% of the predicted value, 
outpatient 
 
Prospective, randomized, 
controlled, double-blind 
study 
Pulmonary rehabilitation 
 
17, 7/10, 250 mg of testosterone 
IM at baseline and 12 mg of oral 
stanozolol a day for 27 weeks 
 
Body mass index (BMI), lean body mass, 
anthropometric measures, respiratory  
muscle strength, and functional exercise 
capacity 
Increases in BMI, lean body mass, and 
anthropometric measures of arm and thigh 
circumference 
Burdet, 
1997[78] 
FEV1/FVC ratio ≤ 70% predicted, 
FEV1increase ≤ 10% after albuterol 
inhalation, BMI ≤ ideal body weight, 
outpatient 
Prospective, randomized, 
double blind, controlled 
study 
Pulmonary rehabilitation  
16, 8/8, subcutaneous injection of 
0.15 IU/kg rhGH 
Nutritional status, resting metabolism, 
muscle strength, exercise tolerance, 
dyspnea 
Increases lean body mass in underweight 
patients 
                                  
 
 
